Want to see KOD full AI Analyst Report?
KOD Stock Chart & Stats
$44.90
-$0.42(-4.39%)
At close: 4:00 PM EST
$44.90
-$0.42(-4.39%)
Day’s Range― - ―
52-Week Range$4.39 - $47.84
Previous CloseN/A
Volume87.32K
Average Volume (3M)822.45K
Market Cap
$2.59B
Enterprise Value$1.88B
Total Cash (Recent Filing)$169.53M
Total Debt (Recent Filing)$155.99M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Aug 19, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.17
Shares Outstanding62,578,440
10 Day Avg. Volume962,934
30 Day Avg. Volume822,454
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)9.45
Price to Sales (P/S)0.00
P/FCF Ratio-10.90
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.34
Forecast
1Y Price Target
$60.00Price Target Upside33.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.74
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Ophthalmology PipelineA concentrated, clinical-stage focus on retinal diseases and a proprietary drug design/delivery approach is a durable strategic advantage: if clinical readouts validate extended ocular durability, the company can claim differentiated dosing and adoption benefits versus competitors, supporting long-term commercial positioning in a specialist therapeutic niche.
Improving Loss And Burn TrendMeaningful narrowing of losses and improved cash burn versus prior years indicates management is stabilizing operations. Sustained improvement extends runway and reduces near-term financing frequency, enabling the company to progress clinical milestones with less dilution risk — a durable operational improvement if maintained through upcoming trials.
Lowering LeverageA reduction in reported debt-to-equity provides structural balance-sheet relief for a pre-revenue biotech. Moderate leverage lowers solvency risk and preserves strategic optionality (e.g., partner deals or structured financings). If this trend persists, it improves the company's ability to fund clinical programs without excessive creditor pressure.
Bears Say
No RevenueZero revenue is a fundamental constraint: the business model remains fully dependent on successful clinical outcomes and external funding. Until a commercial product generates recurring sales, the company faces structural uncertainty around sustainable cash generation and must rely on capital markets or partners to fund ongoing R&D.
Persistent Negative Cash FlowLarge, persistent negative operating and free cash flow indicates losses convert to real cash outflows rather than non-cash accounting charges. This ongoing burn structurally increases funding requirements, raises dilution risk, and constrains the company's ability to self-fund development or scale operations absent a revenue inflection or material partnership.
Eroding Equity Base & Funding RiskA materially reduced equity base signals prolonged losses and weaker capital cushions. This erosion reduces financial flexibility, elevates the probability of dilutive financings, and limits ability to absorb clinical setbacks. Long-term viability hinges on clinical progress or sizable external capital/partnerships.
Kodiak Sciences News
KOD FAQ
What was Kodiak Sciences’s price range in the past 12 months?
Kodiak Sciences lowest stock price was $4.39 and its highest was $47.84 in the past 12 months.
What is Kodiak Sciences’s market cap?
Kodiak Sciences’s market cap is $2.59B.
When is Kodiak Sciences’s upcoming earnings report date?
Kodiak Sciences’s upcoming earnings report date is Aug 19, 2026 which is in 38 days.
How were Kodiak Sciences’s earnings last quarter?
Currently, no data Available
Is Kodiak Sciences overvalued?
According to Wall Street analysts Kodiak Sciences’s price is currently Undervalued.
Does Kodiak Sciences pay dividends?
Kodiak Sciences does not currently pay dividends.
What is Kodiak Sciences’s EPS estimate?
Kodiak Sciences’s EPS estimate is -0.96.
How many shares outstanding does Kodiak Sciences have?
Kodiak Sciences has 62,578,440 shares outstanding.
What happened to Kodiak Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kodiak Sciences?
Currently, no hedge funds are holding shares in KOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kodiak Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.00 (33.63% Upside)
$60.00 (33.63% Upside)
Blogger Sentiment
Bullish
KOD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 868.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
820.04%
12-Months-Change
Fundamentals
Return on Equity
-253.85%
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Company Description
Kodiak Sciences
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
KOD Stock 12 Month Forecast
Average Price Target
$60.00
▲(33.63% Upside)
Technical Analysis
Urogen Pharma
―
Nurix Therapeutics
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
33.51% Insiders
10.78% Mutual Funds
0.04% Other Institutional Investors
45.02% Public Companies and
Individual Investors